Connect with us

Hi, what are you looking for?

Current News

Actor Sam Neill reveals blood cancer diagnosis

Actor Sam Neill has revealed he is being treated for stage-three blood cancer, writing in a memoir that he was “possibly dying” from the illness diagnosed a year ago.

The New Zealander, who burst to fame after starring as Dr Alan Grant in the 1993 blockbuster “Jurassic Park”, said he began treatment last March for non-Hodgkin lymphoma.

Neill, 75, makes the revelation in his book “Did I Ever Tell You This?”, which is being released next week.

In the opening chapter, written while undergoing chemotherapy, Neill said: “The thing is, I’m crook. Possibly dying. I may have to speed this up.” 

The actor told The Guardian he is now in remission but will continue to undergo chemotherapy for the remainder of his life.

“I can’t pretend that the last year hasn’t had its dark moments,” he said.

“But those dark moments throw the light into sharp relief, you know, and have made me grateful for every day and immensely grateful for all my friends. Just pleased to be alive.”

Neill’s vast acting career began in the 1970s and has spanned dozens of roles in TV and film, including “Peaky Blinders”, “The Hunt for Red October”, and “The Piano”. 

He is currently preparing for a role in a television adaptation of Liane Moriarty’s bestselling novel “Apples Never Fall”, which will be filmed in Australia.

When he’s not acting, Neill also runs vineyards in the picturesque Central Otago region of New Zealand’s South Island.

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...